Sign in
4

Changes in Ownership

Rapport Therapeutics, Inc. Filed Acc 0001193125-26-015350

Chief Scientific Officer sold 8,500 shares at an average $26.84 ($228,132)

  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Insider Date Transaction Shares Price Value Owned after D/I
Bredt David Chief Scientific Officer 2026-01-15 Sale 10b5-1 −8,300 $26.83 $222,652 395,775 D
Bredt David Chief Scientific Officer 2026-01-15 Sale 10b5-1 −200 $27.40 $5,480 395,575 D
Open-market sales · 8,500 sh · avg $26.84 · $228,132
Loading xslF345X05/ownership.xml…